La cadena de opciones muestra datos clave de las opciones de acciones de INLIF a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para INLIF..

INLIF (NASDAQ:INLF) Bolsa, Cadena de Opciones

INLIF Ltd is a holding company and does business through its subsidiary. It is engaged in the research, development, manufacturing, and sales of injection molding machine-dedicated manipulator arms also a provider of installation services and warranty services for manipulator arms, and accessories and raw materials for manipulator arms. The company portfolio includes injection molding machine-dedicated manipulator arms, including transverse single and double-axis manipulator arms, transverse and longitudinal multi-axis manipulator arms, and large bullhead multi-axis manipulator arms.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

APTO

CSAI

DSGN

EFOI

EWCZ

GLYC

GRAB

HEES

INLF

LVWR

MGOL

MTRX

NESR

NTIC

RSLS

TNMG

Las acciones de GCL Global suben más del 100% en premercado tras su fusión. Descubre qué otras acciones están en movimiento hoy.

Acciones de GCL Global Holdings (GCL) se disparan un 107%; 20 acciones que se mueven en el premercado

INLIF Ltd

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Maintains $15 Price Target

HC Wainwright &amp; Co. analyst Edward White reiterates Artiva Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTV#NASDAQ">ARTV</a>) with a Buy and maintains $20 price target.

ARTV

HC Wainwright & Co. Reiterates Buy on Artiva Biotherapeutics, Maintains $20 Price Target

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) with a Buy and maintains $14 price target.

IMNN

HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $14 Price Target

Morgan Stanley analyst Craig Hettenbach initiates coverage on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) with a Overweight rating and announces Price Target of $165.

Initiation

Morgan Stanley Initiates Coverage On Tenet Healthcare with Overweight Rating, Announces Price Target of $165

The transaction is anticipated to close later in the second quarter of 2025, subject to standard closing conditions and regulatory approvals.
 &nbsp;

Asset Sales

DLTR

Dollar Tree Agrees To Divest Its Family Dollar Business To Brigade Capital Management And Macellum Capital Management For $1.007B

Sapiens International Corporation&nbsp;N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPNS#NASDAQ">SPNS</a>) (TASE: SPNS), a leading global provider of software solutions for the insurance industry, announced today that its board of directors has approved the distribution of a cash dividend, based on second-half 2024 results, of $0.30 per share, or $16.8 million in total. The dividend is in line with the Company's policy of distributing on a semi-annual basis up to 40% of its annual non-GAAP net income and will be paid on April 16, 2025 to Sapiens' shareholders of record as of April 7, 2025. In addition, the board of directors has approved distribution of a special cash dividend of $0.36 per share, or $20.1M in total. The total cash dividend distribution will be $0.66 per share, or $36.9M. The dividend is subject to withholding of Israeli tax at source at the rate of 25% of the dividend amount payable to each shareholder of record.

Dividends

SPNS

Sapiens Declares $0.30 Quarterly Dividend and Adds $0.36 Special Dividend, Totaling $0.66 Per Share

HC Wainwright &amp; Co. analyst Emily Bodnar maintains Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) with a Buy and lowers the price target from $22 to $19.

ACRV

HC Wainwright & Co. Maintains Buy on Acrivon Therapeutics, Lowers Price Target to $19

Peter Schiff, a renowned economist and financial commentator, has expressed his views on the impact of reversing globalization and hinted at a potential presidential run in 2028.
What Happened: In a detailed thread on X, Schiff referred to Vice President JD Vance&#8216;s address at a recent AI summit, where Vance called &#8216;cheap labor&#8217; a drug for American industries, criticized it for restraining innovation and stated that President Donald Trump intends to roll back 40 years of globalization.
According to Schiff, while globalization has led to the hollowing of America&#8217;s industrial base and the decimation of the middle class, it has also kept consumer prices in check and funneled inflation into financial markets. This, he says, has created an illusion of economic growth.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Vice President <a href="https://twitter.com/JDVance?ref_src=twsrc%5Etfw">@JDVance</a> said that Trump wants to undo 40 years of globalization. While it&#39;s true that globalization has hollowed out America&#39;s industrial base, decimated the middle class, and left us deeply in debt, it's also slowed the rise of consumer prices and directed most…
&mdash; Peter Schiff (@PeterSchiff) <a href="https://twitter.com/PeterSchiff/status/1904566824366154098?ref_src=twsrc%5Etfw">March 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<figcaption class="wp-element-caption">He further stated that President Trump&#8217;s attempts to reverse globalization would result in a redirection of inflation from financial markets to the real economy. This could lead to a collapse in asset prices and a surge in&nbsp;consumer prices and interest rates. Schiff warns that the public, investors, and the Trump administration are unprepared for this economic shift. He predicts that the administration will resort to fiscal bailouts, aggressive rate cuts, and quantitative easing programs from the Federal Reserve. However, Schiff believes that these measures will not&nbsp;have the desired effect. Instead, he suggests that the economy will &#8220;overdose&#8221; on these policies, leading to a potential economic crisis.</figcaption></figure>
SEE ALSO: <a href="https://www.benzinga.com/25/03/44469333/alibabas-tsai-sounds-alarm-on-signs-of-ai-bubble-people-are-building-data-centers-on-speculation">Alibaba&#8217;s Tsai Sounds Alarm On Signs Of AI Bubble In US: &#8216;People Are Building Data Centers On Speculation&#8217;</a>
Why It Matters: The post aligns with Schiff&#8217;s bearish outlook, echoing his 2023 recession warnings, and reflects market concerns as the S&amp;P 500 dipped into a correction in March 2025 amid uncertainty over Trump&#8217;s tariffs.
He hopes that the crisis occurs early enough in Trump&#8217;s term for a Republican Congress to make&nbsp;necessary cuts to government spending&nbsp;and regulations. This, he believes, would allow for the revival of free-market capitalism. Schiff also warned that if it happens late in Trump&#8217;s term, a radical left Democratic party could gain power in 2028, threatening the capitalist system and embracing socialism.
The economist also hinted at a possible presidential run in 2028, stating that the election could be a defining moment for the nation&#8217;s future. &#8220;&#8230;the 2028 election may end up being the defining moment of our nation&#8217;s future. I may throw my hat in the ring,&#8221; stated Schiff.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/general/market-summary/25/03/44488489/rumble-launches-crypto-wallet-for-creators-amid-775-million-tether-investment-we-want-to-take-on-google-head-on-says-ceo">Rumble Launches Crypto Wallet For Creators Amid $775 Million Tether Investment: &#8216;We Want To Take On Google Head On,&#8217; Says CEO</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Peter Schiff Slams JD Vance's 'Cheap Labor' Remarks: Globalization Hollowed US Industry, But Kept Prices In Check, Says Renowned Economist

On March 26, 2025, the Company announced that its wholly-owned subsidiaries have signed agreements with two new partners for mining operations at the partners' facilities in Pennsylvania and Texas.
The Company entered into a three-year master colocation agreement with Mawson Hosting LLC, an affiliate of Mawson Infrastructure Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>), for joint mining operations at its facility in Midland, Pennsylvania. This expansion in Pennsylvania, together with another recently executed 24-month equipment hosting agreement for bitcoin mining at a facility in Edna, Texas, is expected to add around 4.7 EH/s of computing power to the Company's mining operations in North America. The majority of the projects' hashrate is expected to be gradually installed by the second quarter of 2025.

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Canaan Taps Mawson and Texas Partner to Boost North American Crypto Mining Power by Q2 2025

QMMM

QMMM Holdings On March 21, Received Formal Notification From Nasdaq, That Co Has Regained Compliance With Nasdaq Minimum Bid Price Requirement

HC Wainwright &amp; Co. analyst Sean Lee reiterates Corvus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) with a Buy and maintains $11 price target.

CRVS

HC Wainwright & Co. Reiterates Buy on Corvus Pharma, Maintains $11 Price Target

Warren Buffett&#8217;s aversion to Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and cryptocurrencies is well-known, and the legendary investor hasn't made any direct investments in the asset class thus far.
What happened: Buffett gained infamy in cryptocurrency circles when he described Bitcoin as "probably rat poison squared" during Berkshire Hathaway's annual <a href="https://www.benzinga.com/general/24/03/37513063/warren-buffett-says-he-wouldnt-pay-25-for-all-the-bitcoin-in-the-world-he-considers-crypto-rat-poiso">shareholder</a> meeting in 2018. He even prophesied that they would meet a "bad ending."
However, the "Oracle of Omaha" isn't the only Wall Street titan skeptical of digital assets.
Howard Marks:&nbsp; The co-founder of Oaktree Capital Management opined that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/01/36694229/forget-bitcoin-and-gold-says-investment-guru-howard-marks-high-yield-bonds-offer-be">Bitcoin lacks intrinsic value </a>and is far from being a safe investment option in the current market environment.
John Paulson: A billionaire hedge fund manager who founded Paulson &amp; Co., Inc., Paulson described cryptocurrencies as a <a href="https://www.benzinga.com/markets/cryptocurrency/21/08/22721714/crypto-is-a-worthless-bubble-billionaire-subprime-shorter-john-paulson-thinks">worthless bubble.</a>&nbsp;
The renowned subprime short investor advised against investing in the asset class, stating that he would not even short it.
Peter Lynch: The former manager of the <a href="https://www.benzinga.com/personal-finance/25/03/44287485/peter-lynch-said-theres-always-something-to-worry-about-but-success-in-the-stock-market-depends-">hugely successful</a> Magellan Fund at Fidelity Investments has avoided cryptocurrency investments. During a CNBC interview, the legendary stock picker said that he has <a href="https://www.cnbc.com/2023/04/25/famed-investor-peter-lynch-says-he-doesnt-own-any-crypto.html">"no idea"</a> when it comes to cryptocurrencies, but admitted that he does understand blockchains, the technology that powers Bitcoin. 
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/03/44468393/elizabeth-warren-questions-trumps-sec-pick-paul-atkins-on-ftx-ties-conflict-of-interest-over-trump-memecoin">Elizabeth Warren Questions Trump&#8217;s SEC Pick Paul Atkins On FTX Ties, TRUMP Memecoin Conflict Of Interest</a>
While these notable personalities haven't found a compelling reason yet to invest in cryptocurrencies, a few others have seen their views soften over the years.
Ray Dalio, founder of Bridgewater Associates, was critical of Bitcoin's practicality as a currency or store of value back in 2017.&nbsp;
Fast forward to 2025, the billionaire investor<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43128625/ray-dalio-reveals-little-bitcoin-holding-highlights-need-for-alternative-money-but-sees-no-central-bank-adoption"> revealed that he owned Bitcoin</a> and acknowledged its potential as an investment.
Price Action:&nbsp; At the time of writing, Bitcoin was exchanging hands at $87,886.45, up 1.40% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Notably, the asset has increased by 1,233% in the last five years and a staggering 35,604% in the last ten.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/03/44468143/sam-altman-founded-worldcoin-network-beats-bitcoin-ethereum-with-11-rally-amid-visa-partnership-reports">Sam Altman-Founded Worldcoin Network Beats Bitcoin, Ethereum With 11% Rally Amid Visa Partnership Reports</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Warren Buffett Is A Known Crypto Critic, But These Wall Street Titans Also Share The Oracle Of Omaha's Skepticism

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) with a Buy and raises the price target from $165 to $180.

HC Wainwright & Co. Maintains Buy on Franco-Nevada, Raises Price Target to $180

Morgan Stanley analyst James Faucette upgrades Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) from Equal-Weight to Overweight and lowers the price target from $55 to $46.

Upgrades

GLBE

Morgan Stanley Upgrades Global E Online to Overweight, Lowers Price Target to $46

For fiscal year 2025, the Company maintains its guidance, expecting total revenues to be in the range of US$900 million to US$1.1 billion. For the first quarter of 2025, the Company expects total revenues to be approximately US$75 million. For the second quarter of 2025, the Company expects total revenues to be in the range of US$120 million and US$150 million.

Guidance

Canaan Expects Q2 Revenue Of $120M-$150M Vs $155M Est, FY25 Revenue Of $0.9B-$1.1B Vs $588.2M Est

U.S. stock futures were trading lower on Wednesday, after advancing for three consecutive sessions. Futures of major benchmark indices were lower in premarket trading.
Investors are reacting cautiously to President Donald Trump&#8216;s mixed tariff signals. While stocks rallied on hints of potential duty reductions, Trump also announced impending tariffs on pharma and auto, along with secondary tariffs on Venezuelan oil and gas buyers. The volatility reflects the market&#8217;s sensitivity to the administration&#8217;s fluctuating trade stance.
The 10-year Treasury yield stood at 4.33%, while the two-year yield was at 4.02%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is an 88.4% chance that the Federal Reserve will keep the interest rates unchanged during its May meeting. 
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.15%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.12%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.16%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.21%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Wednesday. The SPY was down 0.18% to $574.44, while the QQQ declined 0.24% to $492.26, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From Last Session:
Consumer discretionary, communication services, financials, and energy sectors led a broad market rally on Tuesday, driving U.S. stocks higher.
Whereas, utilities, consumer staples, real estate and health care sectors declined.
On the economic front, the U.S. home prices hit a 20th record high, S&amp;P Case-Shiller showed a 4.1% annual rise in January. March saw a further decline in consumer confidence, according to the Conference Board, with the current conditions index slipping to 92.9, below expectations and marking a fourth consecutive monthly drop.
The Dow Jones index rose 4 points or 0.01% on Tuesday to 42,587.50, whereas the S&amp;P 500 index was up 0.16% at 5,776.65. Nasdaq Composite notched a 0.46% gain to end at 18,271.86, and the small-cap gauge, Russell 2000, declined 0.66% to 2,095.38.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>0.46%</td>
<td>18,271.86</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.16%</td>
<td>5,776.65</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.01%</td>
<td>42,587.50</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.66%</td>
<td>2,095.38</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts:
The director of global macro at Fidelity Investments, Jurrien Timmer, highlighted in an X post that the market has gone from &#8220;above-trend to on-trend.&#8221;
According to his technical analysis, using Bollinger Bands, things are starting to look more balanced again after the S&amp;P 500 index had slipped into the correction.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Technically, things are starting to look more balanced again. The chart below shows detrended Bollinger Bands for the S&amp;P 500. That's a fancy way of showing how many deviations the market is from its trendline. We were at +1 and are now at zero. In other words, the market has… <a href="https://t.co/4NKhFIuOgk">pic.twitter.com/4NKhFIuOgk</a>
&mdash; Jurrien Timmer (@TimmerFidelity) <a href="https://twitter.com/TimmerFidelity/status/1904559651104125303?ref_src=twsrc%5Etfw">March 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Morgan Stanley&#8217;s chief equity strategist, Mike Wilson, maintained a 6,500 price target on the S&amp;P 500 index, with support at 5,500 points.
He was overweight on financials, industrials, energy and utilities. Whereas, he was underweight the Consumer in all styles.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Morgan Stanley&#39;s chief equity strategist Mike Wilson &#x1f4e2; Maintains 6,500 <a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a> price target &#x1f4e2;Overweight Financials, Industrials, Energy, Utes &#x1f4e2;Underweight the Consumer in all styles &#x1f4e2;5,500 support holds unless more severe slowing in economy, which is not our base case… <a href="https://t.co/RczZwCSGtD">pic.twitter.com/RczZwCSGtD</a>
&mdash; Seth Golden (@SethCL) <a href="https://twitter.com/SethCL/status/1904497853361164379?ref_src=twsrc%5Etfw">March 25, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Wilson, in his weekly note, said that a Fed put is more likely than a Trump put.
&#8220;Investors are now very focused on the April 2nd reciprocal tariff deadline. While this catalyst could offer some incremental clarity on tariff rates and countries and products in scope, we think it&#8217;s more a starting point for tariff negotiations, as opposed to a clearing event. In short, a Fed put seems closer to being in the money than a Trump put though it probably would require material labor weakness or choppier credit and funding markets,&#8221; he stated.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep an eye on Wednesday:
<ul>
<li>Durable goods orders data is set to be released at 8:30 a.m. ET.</li>
</ul>
<ul>
<li>St. Louis Fed President Alberto Musalem is scheduled to speak at 1:10 p.m. ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) surged 12.44% in premarket on Wednesday after the video game retailer announced a Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) treasury strategy and reported fourth-quarter adjusted earnings of 30 cents per share, beating analyst estimates of eight cents per share.</li>
</ul>
<ul>
<li>Theratechnologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>) soared 53.25% after the company received FDA approval for EGRIFTA WR&#x2122; (Tesamorelin F8) to treat excess visceral abdominal fat in adults with HIV and Lipodystrophy.</li>
</ul>
<ul>
<li>Surgepays Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SURG#NASDAQ">SURG</a>) zoomed 73.19% on better-than-expected FY24 sales results.</li>
</ul>
<ul>
<li>CISO Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CISO#NASDAQ">CISO</a>) was up 16.04% after the company said it paid off its highest-interest loans as part of its ongoing efforts to strengthen its balance sheet.</li>
</ul>
<ul>
<li>Windtree Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) jumped 9.15% after it had recently announced that it regained compliance status with Nasdaq regarding its listing rule standards.</li>
</ul>
<ul>
<li>Humacyte Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) dropped 22.78% after announcing the pricing of its $50 million public offering of 25 million common shares at $2.00 per share.</li>
</ul>
Commodities, Gold, And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.70% to hover around $69.48 per barrel.
Gold Spot US Dollar declined 0.03% to hover around $3,019.12 per ounce. Its previous record high stood at $3,057.51 per ounce.
Asian markets closed on a mixed note on Wednesday. China&#8217;s CSI 300 and India's S&amp;P BSE Sensex index fell in trade. Whereas, Hong Kong's Hang Seng, South Korea's Kospi, Japan's Nikkei 225, and Australia's ASX 200 index advanced. European markets were also mixed in early trade.
Image Via Shutterstock

Analyst Color

Earnings

Equities

Government

Regulations

Bonds

Commodities

Treasuries

Economics

Federal Reserve

ETFs

General

CISO

HUMA

SURG

THTX

WINT

US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert

Earnings Beats

Canaan Q4 2024 GAAP EPS $0.33 Beats $(0.09) Estimate, Sales $88.767M Beat $85.889M Estimate

Morgan Stanley analyst Devin McDermott reinstates Ovintiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OVV#NYSE">OVV</a>) with a Overweight and announces $57 price target.

Morgan Stanley Reinstates Overweight on Ovintiv, Announces $57 Price Target

Canaan Announced That Wholly Owned Subsidiaries Of Canaan Have Signed Agreements That Expand The Company's Self-mining Capabilities At Two New Partners' Mining Facilities In Pennsylvania And Texas

HC Wainwright &amp; Co. analyst Kevin Dede reiterates BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy and maintains $7 price target.

FUFU

HC Wainwright & Co. Reiterates Buy on BitFuFu, Maintains $7 Price Target

Press Releases

INLIF LIMITED Announces Closing of US$8 Million Initial Public Offering

Nuburu

ClearSign Technologies Corporation - Common Stock

ClearSign Technologies

Chicago Rivet & Machine

Desktop Metal

Eastern

Gencor Industries

Greenland Technologies Holding Corporation - Ordinary Shares

Greenland Technologies

Highway Holdings

Hurco Companies

INLIF

JE Cleantech Holdings Limited - Ordinary Shares

JE Cleantech Hldgs

Laser Photonics Corporation - Common Stock

Laser Photonics

Li Bang International Corporation Inc. - Ordinary Shares

Li Bang International

LiqTech International, Inc. - Common Stock

LiqTech Intl

Micropolis Holding Company Ordinary Shares

Micropolis Hldgs

Markforged Holding Corporation Common Stock

Markforged Holding

Nephros

Perma-Pipe International Holdings, Inc. - Common Stock

Perma-Pipe Inlt Hldgs

Rain Enhancement Technologies Holdco, Inc. - Class A Common Stock

Rain Enhancement

374Water

Taylor Devices

Techprecision

CleanCore Solutions Inc. Class B Common Stock

Comments

INLIF

INLIF (INLF) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL